查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2144016

核子醫學與PET市場展望報告：全球結構、預測、競爭趨勢、治療診斷學與AI/工作流程貨幣化（2025-2036年）

Global Nuclear Medicine & PET Market Horizon Report: Market Structure, Forecasts, Competitive Dynamics, Theranostics, and AI / Workflow Monetization, 2025A-2036E
出版日期: | 出版商: Marketstrat, Inc. | 英文 178 Pages | 訂單完成後即時交付

價格

報告摘要

這份 Marketstrat® Horizon 報告對核醫影像生態系統進行了詳盡的全球分析，涵蓋了更廣泛的PET、SPECT、放射性藥物、診療治療診斷學、同位素、軟體以及醫療機構的接受能力，預測期從2025A 到2036E。本報告的目標讀者包括分子影像設備原始設備製造商（OEM）、放射性藥物製造商、同位素及生產供應商、核醫藥局和分銷機構、軟體和劑量測定平台、企業策略和發展團隊、投資者、醫療機構以及其他核醫領域的商業領袖。

本報告將設備系統、運作中部署基礎、升級和擴容的出貨量、平均售價（ASP）、服務和售後市場、診斷放射性藥物和治療產品的需求曲線、醫用同位素和製造系統、償付、治療設施容量以及單獨收益化的AI 和工作流程整合到一個統一的決策模型中。

許多市場研究將設備和放射性藥物分開討論，或假設臨床機會可以直接轉化為收入。本報告對核子醫學的兩大經濟支柱進行整體分析，清楚闡述了每個領域的獨特經濟狀況，包括服務、軟體、同位素供應、分銷、償付和醫療服務提供者營運。核心問題是：隨著核子醫學從以掃描儀為中心的模式向涵蓋診斷、治療、供應、工作流程和醫療服務提供者能力的整合作業系統轉變，價值將在哪裡累積？

本分析採用 Markintel®（Marketstrat 的專有調查方法和戰略框架）構建，將自下而上的全球市場模型與有關監管、臨床實踐、償付、公司、採購、製造和醫療保健組織運營的經驗資料相結合。

已解答主要問題

  • 價值從醫療器材轉移到診斷和治療放射性藥物的速度會有多快？哪一層會繼續成為控制點？
  • 隨著Tc-99m和FDG技術的成熟，哪些診斷類別將逐步成長？此外，PSMA、心臟和神經PET在商業性有何區別？
  • 數位PET/CT、長場PET、PET/MR和SPECT/CT將以多快的速度改變現有設備的配置？
  • 放射性配體療法要獲得批准並成為醫療覆蓋覆蓋的治療方案，必須滿足哪些條件？
  • 哪些同位素、製造、分銷和供應商的產能限制最有可能限制可實現的收入？
  • 人工智慧、量化和劑量測量軟體在哪些領域有可能成為獨立的收入來源？
  • 北美、歐洲、中國、日本、韓國、印度和其他新興地區的優先事項有何不同？

市場概覽

核子醫學正從以設備為中心的模式市場轉向涵蓋診斷和治療的一體化作業系統。放射性藥物佔據了市場價值的很大一部分，並推動了市場的大部分成長。雖然診斷領域仍然是最大的收入來源，但治療領域成為主要的成長引擎。

該設備繼續發揮接入平台的作用。隨著數位化PET/CT、長場PET、PET/MR和SPECT/CT的比例不斷增加，該設備正變得更加數位化、混合化和可量化，同時，服務、軟體和升級也在不斷提升每個已部署系統的生命週期價值。

成長軌跡並非一成不變。成熟的Tc-99m和FDG類別繼續保持其規模。 PSMA、心臟、神經和特殊PET開闢新的產品和工作流程機會。放射性配體療法日益擴大治療市場，但它依賴於合格同位素的供應、產品專用生產、分銷、保險償付、合格人員、治療室、治療安排以及療程的完成。

北美仍然是最大的商業市場，而歐洲則擁有大規模的設備安裝量和強大的臨床基礎。中國、印度和其他亞太地區正透過多種因素擴大市場佔有率，包括設備擴充、在地化生產、公共採購、私營部門對癌症治療的投資以及醫療服務提供者的發展。本報告基於基準情景、樂觀情景和悲觀情景，對這些發展路徑進行了定量分析。

主要市場趨勢

  • 1.治療診斷學改變市場的重心。放射性配體療法將診斷選擇、醫用同位素、藥物生產、分銷、醫療服務提供者獲取途徑、劑量測定和長期後續觀察環節連結起來。商業性成功越來越依賴管理整個流程的能力。
  • 2.診斷放射性藥物仍是最大的收入來源。雖然診斷領域的成長轉向心臟、神經、PSMA 和特殊 PET，但已建立的Tc-99m 和 FDG 途徑繼續支撐著檢測量、已安裝設備、服務和區域放射性藥物網路。
  • 3.數位PET改變高階設備的競爭格局。數位PET/CT憑藉其替代現有設備的優勢、劑量效率、處理能力和定量一致性，正獲得越來越多的市場佔有率。早在長場PET和全身PET成為大規模應用領域之前，它們就已經對高階設備的競爭格局產生了顯著影響。
  • 4.SPECT 仍佔有重要的戰略地位。雖然專用 SPECT 系統的構成比有所下降，但 SPECT 設備的部署數量仍然最多。 SPECT/CT 的重要性日益凸顯，這體現在其逐漸取代混合設備、應用於心臟影像、定量影像、治療診斷學和劑量測定等領域。
  • 5.同位素處理能力必須在每個階段進行評估。本報告區分了已公佈、在建、已經過核准、已運作中、已客戶認證、已分配、已發布、已交付和管理等階段的處理能力。這是因為收入只有在後期階段才會顯現。
  • 6.醫療機構的容量是一個商業阻礙因素。人員配備、認證使用者、檢查室、保險公司批准、放射治療計劃調整、輻射安全以及重複治療療程的承諾決定了獲得認證的醫療機構實際能夠治療的患者數量。
  • 7.人工智慧的商業化主要集中在特定應用場景。最具盈利的應用領域包括腫瘤定量分析、治療診斷學劑量測定、心臟和神經系統分析、報告產生、臨床試驗分析以及操作調整。嵌入掃描器的軟體與供應商用於獲利的軟體是分開處理的。
  • 8.商業機會因地區和收入來源而異。一個具有吸引力的設備市場可能放射性藥物供應有限，而一個蓬勃發展的診斷市場可能缺乏足夠的治療能力。各國的策略必須考慮核准情況、保險償付、本地生產、分銷、服務、人力資源以及醫療機構的準備。

目錄

第1章 執行摘要

  • 全球核子醫學市場展望
  • 主要市場問題
  • 市場價值的轉變
  • 臨床和買方結構
  • 戰略框架的整合
  • 區域市場展望
  • 科技、治療診斷學與人工智慧的展望
  • 競爭格局展望
  • 償付、供應和醫療服務提供者能力展望
  • 情境展望
  • 戰略重點
  • 顯著趨勢
  • 經營團隊結論

第2章 調查方法

  • 本報告的範圍和目標
  • 本報告的定位和排除範圍
  • 研究基礎和證據等級
  • 市場定義與分母結構
  • 細分框架和報告慣例
  • 調查和模型工作流程
  • 關於設備、安裝單元數量和服務的調查方法
  • 放射性藥物的調查方法
  • 狹義人工智慧與工作流程調查方法
  • 區域和國家特定預測的調查方法
  • 競爭分析與策略框架調查方法
  • 場景設計、品質保證（QA）和一致性驗證
  • 解釋的局限性和指南

第3章 全球市場結構、預測與策略框架

  • 本節執行摘要及要點
  • 全球市場概覽
  • 場景範圍
  • 設備和系統市場
  • 實施記錄和技術遷移
  • 服務和售後市場
  • 診斷用放射性藥物
  • 用於治療的放射性藥物
  • 放射性藥物價值的轉變
  • 狹義人工智慧和工作流程的商業化
  • 區域市場結構
  • 臨床應用及買家視角
  • 戰略框架架構
  • M3市場動量矩陣
  • M-TEM技術演進矩陣
  • T-DIC技術擴散/影響曲線
  • 解決方案部署和成長矩陣以及 ARC-INDEX
  • 升級包階梯
  • 按叢集的競爭格局
  • 各部分要點

第4章 競爭結構、企業定位與策略控制

  • 經營團隊要點
  • 競爭相關問題：領導地位正向路徑控制轉變。
  • 由 8個叢集組成的競爭性架構
  • 按分母分類的競爭定位
  • 競爭控制方面
  • GTM 成長與成熟矩陣
  • 叢集1：整合分子成像 OEM 和軟體棧
    • Cluster Thesis
    • GE HealthCare
    • Siemens Healthineers
    • United Imaging Healthcare
    • Royal Philips
    • Mediso
    • Spectrum Dynamics Medical
  • 叢集2：診斷放射性藥物特許經營權
    • Cluster Thesis
    • Lantheus
    • Telix Pharmaceuticals
    • GE HealthCare
    • Bracco/Blue Earth Diagnostics
  • 叢集3：治療性放射性藥物和治療診斷學公司
    • Cluster Thesis
    • Novartis
    • Eli Lilly/POINT Biopharma
    • Bristol Myers Squibb/RayzeBio
    • AstraZeneca/Fusion Pharmaceuticals
    • ITM/Lumara Bio
    • Clarity Pharmaceuticals
    • Perspective Therapeutics
  • 治療管線結構
  • 叢集4：同位素、產生器、CDMO 和分銷基礎設施
    • Cluster Thesis
    • Eckert &Ziegler
    • SHINE
    • Cardinal Health
    • Curium
    • Jubilant, Nucleus, and BWXT
  • 叢集5：定量分析、劑量測定與影像增強
    • Cluster Thesis
    • GE HealthCare/MIM
    • Hermes Medical Solutions
    • Subtle Medical
    • Spectrum Dynamics and AIQ Solutions
  • 叢集6：企業工作流程、報表與編配
  • 叢集7：醫療服務提供者網路、行動存取和治療診斷學中心
  • 叢集8：生命科學、臨床影像與放射性藥物品管（QC）軟體
  • 重點公司概覽
  • 贏家、挑戰與戰略分水嶺
    • 強勁的競爭者
    • 課題
  • 併購與合作展望
  • 相關人員的策略意義
  • 需要注意的徵兆
  • 本節概要

第5章 區域與國家特定市場分析

  • 給經營團隊的建議
  • 區域市場概覽
  • 區域價值結構與情境暴露
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
  • 中國
  • 日本和韓國
    • 日本
    • 韓國
  • 印度
  • 亞太其他地區
    • 澳洲和紐西蘭
    • 新加坡、台灣及東南亞
  • 拉丁美洲
    • 巴西
    • 墨西哥
  • 中東和非洲
    • 波灣合作理事會
    • 南非
    • 北非和其他非洲國家
  • 主要國家的需求與經營環境
  • 各國企業發展準備狀況概述
  • 區域經營模式
  • 戰略意義
  • 需要注意的徵兆
  • 本節結論

第6章 放射性同位素的償付、供應、製造和提供者能力

  • 給經營團隊的建議
  • 市場相關問題：商業性能是相互關聯的。
  • 還款機制
    • 美國診斷支付系統
    • 治療費用和醫療機構經濟狀況
    • 全球支付模式的典型範例
  • 診斷用放射性藥物的供應
  • 治療性同位素和製造系統
  • 產能轉型與製造現狀
  • 供應商的運作能力和員工人數
    • 勞動力
    • 治療過程的負擔
    • 設施成熟度
  • 生產能力管理要素
  • 醫療保健提供者的典型概況
  • 提供者的經濟和資本相關決策
  • 廢棄物、安全和品質
  • 對該地區的影響
  • 相關人員的策略意義
  • 需要注意的徵兆
  • 本節結論

第7章 情境展望、策略重點與行動計劃

Report Overview

This Marketstrat® Horizon report provides an in-depth global analysis of Nuclear Medicine imaging and the wider PET, SPECT, radiopharmaceutical, theranostics, isotope, software, and provider-capacity ecosystem from 2025A to 2036E. It is written for molecular-imaging OEM executives, radiopharmaceutical companies, isotope and manufacturing suppliers, nuclear-pharmacy and distribution organizations, software and dosimetry platforms, corporate strategy and development teams, investors, providers, and commercial leaders with exposure to Nuclear Medicine.

The report brings equipment systems, the active installed base, replacement and expansion shipments, realized ASPs, service and aftermarket, diagnostic radiopharmaceuticals, therapeutic product curves, medical-isotope and manufacturing readiness, reimbursement, treatment-site capacity, and separately monetized AI and workflow into one reconciled decision model.

Many market studies separate equipment from radiopharmaceuticals, or assume that clinical opportunity converts directly into revenue. This report analyzes both economic pillars of Nuclear Medicine together while keeping the distinct economics of service, software, isotope supply, distribution, reimbursement, and provider operations visible. Its central question: where will value accumulate as Nuclear Medicine shifts from a scanner-centered modality to an integrated diagnostic, therapeutic, supply, workflow, and provider-capacity operating system?

The analysis was developed through Markintel®, Marketstrat's proprietary research methodology and strategic framework stack, combining a bottom-up global market model with regulatory, clinical, reimbursement, company, procurement, manufacturing, and provider-operating evidence.

Key Questions Answered

  • How fast does value migrate from equipment toward diagnostic and therapeutic radiopharmaceuticals, and which layers remain control points?
  • Which diagnostic categories carry incremental growth as Tc-99m and FDG mature, and how do PSMA, cardiac, and neuro PET differ commercially?
  • How quickly do digital PET/CT, long-axial-field-of-view PET, PET/MR, and SPECT/CT reshape the installed base?
  • What has to be true for radioligand therapy approvals to become completed, paid treatment courses?
  • Which isotope, manufacturing, distribution, and provider-capacity constraints are most likely to limit realized revenue?
  • Where can AI, quantification, and dosimetry software earn a separately paid revenue stream?
  • How do priorities differ across North America, Europe, China, Japan and South Korea, India, and other emerging regions?

Market Snapshot

Nuclear Medicine is moving from a modality-centered equipment market toward an integrated diagnostic and therapeutic operating system. Radiopharmaceuticals account for most of the market's value and most of its growth. Diagnostics remain the largest revenue layer; therapeutics become the principal growth engine.

Equipment remains the access platform. The fleet becomes more digital, hybrid, and quantitative as digital PET/CT, long-axial-field-of-view PET, PET/MR, and SPECT/CT gain weight, while service, software, and upgrades raise the lifetime value of each installed system.

Growth does not follow one uniform path. Mature Tc-99m and FDG categories retain scale. PSMA, cardiac, neuro, and specialty PET open new product and workflow opportunities. Radioligand therapy expands the therapeutic market but depends on qualified isotope supply, product-specific manufacturing, distribution, reimbursement, licensed staff, treatment rooms, scheduling, and course completion.

North America remains the largest commercial market and Europe retains a large installed and clinical base. China, India, and the rest of Asia-Pacific gain share through different mixes of equipment expansion, local production, public procurement, private oncology investment, and provider development. The report quantifies these paths under Base, Bull, and Bear scenarios.

Key Market Trends

  • 1. Theranostics is shifting the market's center of gravity. Radioligand therapy links diagnostic selection, medical isotopes, drug-product manufacturing, distribution, provider activation, dosimetry, and longitudinal follow-up. Commercial advantage increasingly depends on managing the complete pathway.
  • 2. Diagnostic radiopharmaceuticals remain the largest revenue pool. Growth inside diagnostics is moving toward cardiac, neuro, PSMA, and specialty PET, while established Tc-99m and FDG pathways continue to support procedure volume, installed equipment, service, and regional radiopharmacy networks.
  • 3. Digital PET is changing premium equipment competition. Digital PET/CT expands through replacement, dose efficiency, throughput, and quantitative consistency. Long-axial-field-of-view and total-body PET influence premium competition well before they become large installed-base categories.
  • 4. SPECT stays strategically important. SPECT-only systems decline in mix, yet the SPECT fleet remains the largest installed base. SPECT/CT gains relevance through hybrid replacement, cardiology, quantitative imaging, theranostics, and dosimetry.
  • 5. Isotope capacity has to be assessed by stage. The report distinguishes announced, constructed, licensed, operating, customer-qualified, allocated, released, delivered, and administered capacity, because only the later stages translate into revenue.
  • 6. Provider capacity becomes a binding commercial constraint. Workforce, authorized users, rooms, payer authorization, dose scheduling, radiation safety, and repeat treatment-course commitments determine how many patients a licensed site can actually treat.
  • 7. AI monetization concentrates in defined use cases. The strongest paid opportunities sit in oncology quantification, theranostics dosimetry, cardiac and neuro analysis, reporting, trial analytics, and operational coordination. Embedded scanner software is treated separately from vendor-monetized software.
  • 8. Regional opportunity is revenue-layer specific. An attractive equipment market may have limited radiopharmaceutical access, and a strong diagnostic market may lack therapy capacity. Country strategy has to reflect registration, reimbursement, local production, distribution, service, workforce, and provider readiness.

Competitive Structure

Marketstrat organizes the market into eight strategic clusters: integrated molecular-imaging OEMs and software stacks; diagnostic radiopharmaceutical franchises; therapeutic radiopharma and theranostics companies; isotope, generator, CDMO, and distribution infrastructure; quantification, dosimetry, and image-enhancement specialists; enterprise workflow, reporting, and orchestration platforms; provider networks, mobile access, and theranostics centers; and life-sciences, trial-imaging, and radiopharma-QC software.

Within each cluster, the report examines the relevant revenue denominator, where commercial control sits, product and technology maturity, installed-base and distribution advantages, isotope and provider dependencies, geographic position, partnership and acquisition logic, execution risks, and signals to monitor over the next 12 to 24 months. Equipment share, diagnostic product share, therapeutic product share, isotope control, software adoption, and provider access are treated as separate competitive measures.

Companies covered include GE HealthCare, Siemens Healthineers, United Imaging Healthcare, Philips, Mediso, Spectrum Dynamics Medical, Lantheus, Telix Pharmaceuticals, Novartis, Eli Lilly / POINT Biopharma, Bristol Myers Squibb / RayzeBio, AstraZeneca / Fusion Pharmaceuticals, ITM / Lumara Bio, Clarity Pharmaceuticals, Perspective Therapeutics, Curium, Bracco / Blue Earth Diagnostics, Jubilant Pharmova, Cardinal Health, Eckert & Ziegler, SHINE Technologies, Nucleus RadioPharma, BWX Technologies, NorthStar Medical Radioisotopes, TerraPower Isotopes, Nusano, AdvanCell, Hermes Medical Solutions, Subtle Medical, AIQ Solutions, Sectra, Visage Imaging / Pro Medicus, LabLogic, and Elysia-Raytest, along with selected regional isotope, radiopharmacy, CDMO, mobile PET, and provider-network operators.

What's Inside

Global market and forecast architecture. Core global market model, 2025A–2036E, built from five additive revenue layers, with Base, Bull, and Bear scenarios, value-migration analysis, forecast triggers, and denominator definitions that prevent double counting.

Equipment, installed base, and service. Legacy and digital SiPM PET/CT, long-axial-field-of-view and total-body PET/CT, PET/MR, SPECT/CT, and SPECT-only systems; active installed base, replacement and expansion shipments, realized ASPs, technology mix, and service and lifecycle value.

Diagnostic and therapeutic radiopharmaceuticals. Tc-99m and established SPECT products, FDG, PSMA PET, SSTR imaging, cardiac PET tracers, amyloid, tau, and other neuro PET, specialty PET, commercial radioligand therapies, and late-stage therapeutic cohorts across Lu-177, Ac-225, Pb-212, Cu-67, Y-90, and I-131 strategies.

Enabling ecosystem and provider capacity. Mo-99 / Tc-99m generators, cyclotrons, medical-isotope supply, CDMO and drug-product manufacturing, radiopharmacy and distribution, reimbursement and coding, provider licensing, workforce and treatment rooms, site activation, and course completion.

Strategic frameworks. The Markintel® framework stack, including the M³ Market Momentum Matrix, M-TEM, T-DIC, Solution Adoption & Growth Matrix, ARC-Index, Upgrade & Package Ladder, GTM Growth-Maturity Matrix, Ecosystem Collaboration Matrix, and a competitive control-plane view.

Competitive, regional, and strategic analysis. Eight competitive clusters, company spotlights, therapeutic pipeline structure, M&A and partnership outlook, regional forecasts, country operating-readiness, commercial archetypes, stakeholder priorities, and a 12–24 month action agenda.

Geographic coverage. North America, Europe, China, Japan and South Korea, India, Rest of Asia-Pacific, Latin America, and the Middle East and Africa, with country-level analysis of the United States, Canada, Germany, France, the United Kingdom, Italy, Spain, China, Japan, South Korea, India, Australia / New Zealand, Brazil, Mexico, Saudi Arabia / UAE, and South Africa.

Who Should Read This Report

  • Molecular-imaging OEMs assessing digital PET and SPECT/CT replacement, LAFOV timing, PET/MR positioning, and service attachment
  • Diagnostic and therapeutic radiopharmaceutical companies testing category growth, product curves, launch timing, and distribution access
  • Isotope producers, CDMOs, and radiopharmacy networks
  • AI, dosimetry, and workflow vendors seeking use cases with a credible paid model
  • Providers and health systems planning or expanding Nuclear Medicine and theranostics programs
  • Corporate strategy and corporate development teams
  • Investors, private equity, banks, and advisory firms
  • Government and public-sector programs focused on isotope resilience, access, and capacity

Why This Report

Clinical momentum creates the opportunity; product supply, payment, and productive provider capacity decide how much of it becomes revenue. This report separates clinical potential from commercial readiness, so readers can test market denominators, product curves, manufacturing claims, site capacity, competitive control, and scenario risk in one consistent structure.

Use the report to evaluate market-entry assumptions, size adjacent revenue pools, prioritize regions and buyer segments, benchmark competitors, assess partnership and acquisition targets, identify companies that control strategic bottlenecks, or challenge an existing Nuclear Medicine or theranostics forecast.

Report Details

  • Title: Global Nuclear Medicine & PET Market Horizon
  • Subtitle: Market Structure, Forecasts, Competitive Dynamics, Theranostics, and AI / Workflow Monetization, 2025A–2036E
  • Type: Marketstrat® Horizon Report (flagship, in-depth)
  • Report ID: MINTH-02103
  • Publication: August 2026
  • Forecast Period: 2025A–2036E
  • Length: 178 pages
  • Content: 81 tables and 33 figures, including proprietary strategic frameworks
  • Format: PDF digital delivery
  • Regional Coverage: North America | Europe | China | Japan and South Korea | India | Rest of Asia-Pacific | Latin America | Middle East and Africa
  • Country Coverage: United States, Canada, Germany, France, United Kingdom, Italy, Spain, China, Japan, South Korea, India, Australia / New Zealand, Brazil, Mexico, Saudi Arabia / UAE, and South Africa
  • License Options: Individual ($4,950), Team ($5,450), Enterprise ($8,950)

Table of Contents

SECTION 1: EXECUTIVE SUMMARY

  • 1.1 GLOBAL NUCLEAR MEDICINE MARKET OUTLOOK
  • 1.2 CORE MARKET THESIS
  • 1.3 MARKET VALUE MIGRATION
  • 1.4 CLINICAL AND BUYER STRUCTURE
  • 1.5 STRATEGIC FRAMEWORK SYNTHESIS
  • 1.6 REGIONAL MARKET OUTLOOK
  • 1.7 TECHNOLOGY, THERANOSTICS, AND AI OUTLOOK
  • 1.8 COMPETITIVE OUTLOOK
  • 1.9 REIMBURSEMENT, SUPPLY, AND PROVIDER CAPACITY OUTLOOK
  • 1.10 SCENARIO OUTLOOK
  • 1.11 STRATEGIC PRIORITIES
  • 1.12 SIGNALS TO WATCH
  • 1.13 EXECUTIVE CONCLUSION

SECTION 2: RESEARCH SCOPE, DEFINITIONS, AND METHODOLOGY

  • 2.1 SCOPE AND PURPOSE OF THE REPORT
  • 2.2 WHAT THIS REPORT IS AND WHAT IT IS NOT
  • 2.3 RESEARCH FOUNDATION AND EVIDENCE HIERARCHY
  • 2.4 MARKET DEFINITION AND DENOMINATOR ARCHITECTURE
  • 2.5 SEGMENTATION SCHEMA AND REPORTING CONVENTIONS
  • 2.6 RESEARCH AND MODEL WORKFLOW
  • 2.7 EQUIPMENT, INSTALLED BASE, AND SERVICE METHODOLOGY
  • 2.8 RADIOPHARMACEUTICAL METHODOLOGY
  • 2.9 NARROW AI AND WORKFLOW METHODOLOGY
  • 2.10 REGIONAL AND COUNTRY FORECAST METHODOLOGY
  • 2.11 COMPETITIVE ANALYSIS AND STRATEGIC FRAMEWORK METHODOLOGY
  • 2.12 SCENARIO DESIGN, QA, AND RECONCILIATION
  • 2.13 LIMITATIONS AND GUIDANCE FOR INTERPRETATION

SECTION 3: GLOBAL MARKET STRUCTURE, FORECASTS, AND STRATEGIC FRAMEWORKS

  • 3.1 SECTION THESIS AND KEY TAKEAWAYS
  • 3.2 GLOBAL MARKET OVERVIEW
  • 3.3 SCENARIO RANGE
  • 3.4 EQUIPMENT SYSTEMS MARKET
  • 3.5 INSTALLED BASE AND TECHNOLOGY TRANSITION
  • 3.6 SERVICE AND AFTERMARKET
  • 3.7 DIAGNOSTIC RADIOPHARMACEUTICALS
  • 3.8 THERAPEUTIC RADIOPHARMACEUTICALS
  • 3.9 RADIOPHARMA VALUE MIGRATION
  • 3.10 NARROW AI AND WORKFLOW MONETIZATION
  • 3.11 REGIONAL MARKET STRUCTURE
  • 3.12 CLINICAL APPLICATION AND BUYER VIEWS
  • 3.13 STRATEGIC FRAMEWORK ARCHITECTURE
  • 3.14 M³ MARKET MOMENTUM MATRIX
  • 3.15 M-TEM TECHNOLOGY EVOLUTION MATRIX
  • 3.16 T-DIC TECHNOLOGY DIFFUSION AND IMPACT CURVE
  • 3.17 SOLUTION ADOPTION & GROWTH MATRIX AND ARC-INDEX
  • 3.18 UPGRADE & PACKAGE LADDER
  • 3.19 COMPETITIVE IMPLICATIONS BY CLUSTER
  • 3.20 SECTION TAKEAWAYS

SECTION 4: COMPETITIVE STRUCTURE, COMPANY POSITIONING, AND STRATEGIC CONTROL

  • 4.1 EXECUTIVE TAKEAWAYS
  • 4.2 COMPETITIVE THESIS: LEADERSHIP IS SHIFTING TOWARD PATHWAY CONTROL
  • 4.3 EIGHT-CLUSTER COMPETITIVE ARCHITECTURE
  • 4.4 DENOMINATOR-SPECIFIC COMPETITIVE POSITIONS
  • 4.5 COMPETITIVE CONTROL PLANE
  • 4.6 GTM GROWTH-MATURITY MATRIX
  • 4.7 CLUSTER 1: INTEGRATED MOLECULAR-IMAGING OEMS AND SOFTWARE STACKS
    • Cluster Thesis
    • GE HealthCare
    • Siemens Healthineers
    • United Imaging Healthcare
    • Royal Philips
    • Mediso
    • Spectrum Dynamics Medical
  • 4.8 CLUSTER 2: DIAGNOSTIC RADIOPHARMACEUTICAL FRANCHISES
    • Cluster Thesis
    • Lantheus
    • Telix Pharmaceuticals
    • GE HealthCare
    • Bracco / Blue Earth Diagnostics
  • 4.9 CLUSTER 3: THERAPEUTIC RADIOPHARMA AND THERANOSTICS COMPANIES
    • Cluster Thesis
    • Novartis
    • Eli Lilly / POINT Biopharma
    • Bristol Myers Squibb / RayzeBio
    • AstraZeneca / Fusion Pharmaceuticals
    • ITM / Lumara Bio
    • Clarity Pharmaceuticals
    • Perspective Therapeutics
  • 4.10 THERAPEUTIC PIPELINE STRUCTURE
  • 4.11 CLUSTER 4: ISOTOPE, GENERATOR, CDMO, AND DISTRIBUTION INFRASTRUCTURE
    • Cluster Thesis
    • Eckert & Ziegler
    • SHINE
    • Cardinal Health
    • Curium
    • Jubilant, Nucleus, and BWXT
  • 4.12 CLUSTER 5: QUANTIFICATION, DOSIMETRY, AND IMAGE ENHANCEMENT
    • Cluster Thesis
    • GE HealthCare / MIM
    • Hermes Medical Solutions
    • Subtle Medical
    • Spectrum Dynamics and AIQ Solutions
  • 4.13 CLUSTER 6: ENTERPRISE WORKFLOW, REPORTING, AND ORCHESTRATION
  • 4.14 CLUSTER 7: PROVIDER NETWORKS, MOBILE ACCESS, AND THERANOSTICS CENTERS
  • 4.15 CLUSTER 8: LIFE-SCIENCES, TRIAL-IMAGING, AND RADIOPHARMA-QC SOFTWARE
  • 4.16 COMPANY SPOTLIGHT SUMMARY
  • 4.17 WINNERS, PRESSURE POINTS, AND STRATEGIC FAULT LINES
    • Likely Winners
    • Pressure Points
  • 4.18 M&A AND PARTNERSHIP OUTLOOK
  • 4.19 STRATEGIC IMPLICATIONS BY STAKEHOLDER
  • 4.20 SIGNALS TO MONITOR
  • 4.21 SECTION CONCLUSION

SECTION 5: REGIONAL AND COUNTRY MARKET ANALYSIS

  • 5.1 EXECUTIVE TAKEAWAYS
  • 5.2 REGIONAL MARKET OVERVIEW
  • 5.3 REGIONAL VALUE MIX AND SCENARIO EXPOSURE
  • 5.4 NORTH AMERICA
    • 5.4.1 United States
    • 5.4.2 Canada
  • 5.5 EUROPE
    • 5.5.1 Germany
    • 5.5.2 France
    • 5.5.3 United Kingdom
    • 5.5.4 Italy
    • 5.5.5 Spain
  • 5.6 CHINA
  • 5.7 JAPAN AND SOUTH KOREA
    • 5.7.1 Japan
    • 5.7.2 South Korea
  • 5.8 INDIA
  • 5.9 REST OF ASIA-PACIFIC
    • 5.9.1 Australia and New Zealand
    • 5.9.2 Singapore, Taiwan, and Southeast Asia
  • 5.10 LATIN AMERICA
    • 5.10.1 Brazil
    • 5.10.2 Mexico
  • 5.11 MIDDLE EAST AND AFRICA
    • 5.11.1 Gulf Cooperation Council
    • 5.11.2 South Africa
    • 5.11.3 North Africa and Rest of Africa
  • 5.12 SELECTED COUNTRY DEMAND AND OPERATING CONTEXT
  • 5.13 COUNTRY OPERATING-READINESS VIEW
  • 5.14 REGIONAL COMMERCIAL ARCHETYPES
  • 5.15 STRATEGIC IMPLICATIONS
  • 5.16 SIGNALS TO MONITOR
  • 5.17 SECTION CONCLUSION

SECTION 6: REIMBURSEMENT, RADIOISOTOPE SUPPLY, MANUFACTURING, AND PROVIDER CAPACITY

  • 6.1 EXECUTIVE TAKEAWAYS
  • 6.2 MARKET THESIS: COMMERCIAL CAPACITY IS A CHAIN
  • 6.3 REIMBURSEMENT ARCHITECTURE
    • 6.3.1 United States Diagnostic Payment
    • 6.3.2 Therapeutic Payment and Site Economics
    • 6.3.3 Global Payment Archetypes
  • 6.4 DIAGNOSTIC RADIOPHARMACEUTICAL SUPPLY
  • 6.5 THERAPEUTIC ISOTOPE AND MANUFACTURING ARCHITECTURE
  • 6.6 CAPACITY CONVERSION AND MANUFACTURING STATUS
  • 6.7 PROVIDER OPERATING CAPACITY AND WORKFORCE
    • 6.7.1 Workforce
    • 6.7.2 Treatment-Course Burden
    • 6.7.3 Site Maturity
  • 6.8 THE CAPACITY-CONTROL STACK
  • 6.9 PROVIDER ARCHETYPES
  • 6.10 PROVIDER ECONOMICS AND CAPITAL DECISIONS
  • 6.11 WASTE, SAFETY, AND QUALITY
  • 6.12 REGIONAL IMPLICATIONS
  • 6.13 STRATEGIC IMPLICATIONS BY STAKEHOLDER
  • 6.14 SIGNALS TO MONITOR
  • 6.15 SECTION CONCLUSION

SECTION 7: SCENARIO OUTLOOK, STRATEGIC PRIORITIES, AND ACTION AGENDA

  • 7.1 EXECUTIVE TAKEAWAYS
  • 7.2 SCENARIO FRAMEWORK AND GUARDRAILS
  • 7.3 GLOBAL SCENARIO RANGE
  • 7.4 BASE CASE
  • 7.5 BULL CASE
  • 7.6 BEAR CASE
  • 7.7 SCENARIO SENSITIVITY BY REVENUE LAYER
  • 7.8 PRODUCT, TECHNOLOGY, AND USE-CASE SENSITIVITY
  • 7.9 REGIONAL SCENARIO EXPOSURE
  • 7.10 PRINCIPAL SCENARIO DRIVERS
  • 7.11 LEADING INDICATORS AND FORECAST TRIGGERS
  • 7.12 RISK AND OPPORTUNITY MATRIX
  • 7.13 STRATEGIC PRIORITIES BY STAKEHOLDER
  • 7.14 12-24 MONTH ACTION AGENDA
  • 7.15 STRATEGIC OUTLOOK

List of Tables

  • TABLE 1: GLOBAL NUCLEAR MEDICINE MARKET BY REVENUE LAYER, 2025A-2036E
  • TABLE 2: SELECTED VALUE-MIGRATION INDICATORS
  • TABLE 3: DIRECTIONAL CLINICAL AND BUYER MIX
  • TABLE 4: STRATEGIC FRAMEWORK SYNTHESIS
  • TABLE 5: REGIONAL NUCLEAR MEDICINE MARKET OUTLOOK
  • TABLE 6: COMPETITIVE POSITIONING SUMMARY
  • TABLE 7: REIMBURSEMENT, SUPPLY, AND PROVIDER-CAPACITY CONTROL POINTS
  • TABLE 8: GLOBAL NUCLEAR MEDICINE MARKET SCENARIO RANGE
  • TABLE 9: STRATEGIC PRIORITIES BY STAKEHOLDER
  • TABLE 10: SIGNALS THAT WOULD CHANGE THE MARKET VIEW
  • TABLE 11: REPORT SCOPE AND INTERPRETATION
  • TABLE 12: STANDARDIZED SOURCE STACK AND USAGE RULES
  • TABLE 13: CONFIDENCE CLASSIFICATION
  • TABLE 14: NUCLEAR MEDICINE MARKET DENOMINATOR ARCHITECTURE
  • TABLE 15: REPORT-FACING SEGMENTATION SCHEMA
  • TABLE 16: EQUIPMENT AND SERVICE FORECAST CONSTRUCTION
  • TABLE 17: DIAGNOSTIC AND THERAPEUTIC RADIOPHARMACEUTICAL MODELING
  • TABLE 18: NARROW AI AND WORKFLOW REVENUE BOUNDARY
  • TABLE 19: REGIONAL FORECAST ARCHITECTURE
  • TABLE 20: MARKINTEL STRATEGIC FRAMEWORK METHODOLOGY
  • TABLE 21: SCENARIO INTERPRETATION
  • TABLE 22: QA, RECONCILIATION, AND REPRODUCIBILITY
  • TABLE 23: INTERPRETATION GUARDRAILS
  • TABLE 24: GLOBAL NUCLEAR MEDICINE MARKET BY REVENUE LAYER
  • TABLE 25: CONTRIBUTION TO GLOBAL MARKET GROWTH, 2025A-2036E
  • TABLE 26: GLOBAL BASE, BULL, AND BEAR SCENARIO
  • TABLE 27: GLOBAL EQUIPMENT SYSTEMS REVENUE BY SEGMENT
  • TABLE 28: GLOBAL SHIPMENTS AND INSTALLED BASE BY SYSTEM TYPE
  • TABLE 29: GLOBAL EQUIPMENT SERVICE AND AFTERMARKET REVENUE
  • TABLE 30: GLOBAL DIAGNOSTIC RADIOPHARMACEUTICAL MARKET BY CATEGORY
  • TABLE 31: GLOBAL THERAPEUTIC RADIOPHARMACEUTICAL MARKET BY PRODUCT AND COHORT
  • TABLE 32: NARROW VENDOR-NET AI AND WORKFLOW REVENUE BY USE CASE
  • TABLE 33: GLOBAL NUCLEAR MEDICINE MARKET BY REGION
  • TABLE 34: REGIONAL MARKET COMPOSITION, 2025A AND 2036E
  • TABLE 35: DIRECTIONAL GLOBAL MARKET MIX BY CLINICAL APPLICATION
  • TABLE 36: DIRECTIONAL GLOBAL MARKET MIX BY BUYER TYPE
  • TABLE 37: M³ MARKET MOMENTUM MATRIX, REVENUE LAYERS
  • TABLE 38: M³ MARKET MOMENTUM MATRIX, SELECTED TECHNOLOGIES AND USE CASES
  • TABLE 39: M-TEM TECHNOLOGY MATURITY SCORECARD
  • TABLE 40: T-DIC TECHNOLOGY POSITIONING
  • TABLE 41: SOLUTION ADOPTION AND GROWTH POSITIONING
  • TABLE 42: ARC-INDEX READINESS
  • TABLE 43: NUCLEAR MEDICINE UPGRADE & PACKAGE LADDER
  • TABLE 44: MARKET STRUCTURE IMPLICATIONS BY COMPETITIVE CLUSTER
  • TABLE 45: COMPETITIVE CONTROL LAYERS
  • TABLE 46: COMPETITIVE CLUSTER ARCHITECTURE
  • TABLE 47: EQUIPMENT AND INTEGRATED PLATFORM POSITIONING
  • TABLE 48: ESTIMATED 2025A PSMA PET DIAGNOSTIC FRANCHISE SHARE BANDS
  • TABLE 49: THERAPEUTIC COMPETITIVE STRUCTURE
  • TABLE 50: COMPETITIVE CONTROL-PLANE SUMMARY
  • TABLE 51: GTM GROWTH-MATURITY POSITIONS
  • TABLE 52: SELECTED THERAPEUTIC RADIOPHARMACEUTICAL PROGRAMS
  • TABLE 53: INFRASTRUCTURE COMPETITIVE POSITIONS
  • TABLE 54: SELECTED COMPANY POSITIONING
  • TABLE 55: ECOSYSTEM COLLABORATION MATRIX
  • TABLE 56: GLOBAL NUCLEAR MEDICINE MARKET BY REGION
  • TABLE 57: REGIONAL REVENUE-LAYER MIX
  • TABLE 58: 2036 REGIONAL SCENARIO RANGE
  • TABLE 59: SELECTED COUNTRY DEMAND INDICATORS AND MARKET CONTEXT
  • TABLE 60: REGIONAL COMMERCIAL ARCHETYPES
  • TABLE 61: ECONOMIC LAYERS AND ADDITIVE TREATMENT
  • TABLE 62: 2026 US OUTPATIENT PAYMENT ARCHITECTURE
  • TABLE 63: GLOBAL REIMBURSEMENT AND ACCESS ARCHETYPES
  • TABLE 64: DIAGNOSTIC ISOTOPE AND DELIVERY ARCHITECTURES
  • TABLE 65: THERAPEUTIC ISOTOPE LOGISTICS
  • TABLE 66: SELECTED RADIOISOTOPE AND MANUFACTURING PROGRAMS
  • TABLE 67: PRODUCT SCHEDULES AND CAPACITY IMPLICATIONS
  • TABLE 68: PROVIDER ACTIVATION LADDER
  • TABLE 69: CAPACITY-CONTROL METRICS
  • TABLE 70: DIAGNOSTIC AND THERAPY PROVIDER ARCHETYPES
  • TABLE 71: OPERATING RISK CONTROLS
  • TABLE 72: REGIONAL ACCESS AND CAPACITY PRIORITIES
  • TABLE 73: GLOBAL NUCLEAR MEDICINE MARKET SCENARIO RANGE
  • TABLE 74: GLOBAL MARKET BY REVENUE LAYER AND SCENARIO, 2036E
  • TABLE 75: SELECTED SCENARIO-SENSITIVE PRODUCTS AND USE CASES, 2036E
  • TABLE 76: REGIONAL SCENARIO RANGE, 2036E
  • TABLE 77: PRINCIPAL SCENARIO DRIVERS
  • TABLE 78: LEADING-INDICATOR CONTROL TOWER
  • TABLE 79: RISK AND OPPORTUNITY MATRIX
  • TABLE 80: STRATEGIC PRIORITIES BY STAKEHOLDER
  • TABLE 81: ACTION AGENDA

List of Figures

  • FIGURE 1: THERANOSTICS AND SPECIALTY PET RESHAPE THE GLOBAL MARKET
  • FIGURE 2: RADIOPHARMACEUTICALS DRIVE MOST MARKET GROWTH
  • FIGURE 3: NO COMPANY CONTROLS THE COMPLETE NUCLEAR MEDICINE PATHWAY
  • FIGURE 4: GLOBAL MARKET SCENARIO RANGE, 2036E
  • FIGURE 5: MARKET VALUE IS BUILT FROM FIVE ADDITIVE LAYERS
  • FIGURE 6: EVIDENCE BECOMES FORECAST ONLY AFTER DENOMINATOR AND SOURCE TESTS
  • FIGURE 7: THE HORIZON FRAMEWORK STACK CONVERTS EVIDENCE INTO ACTION
  • FIGURE 8: RADIOPHARMACEUTICALS CAPTURE THE MAJORITY OF MARKET GROWTH
  • FIGURE 9: THE FLEET DIGITIZES WITHOUT ABANDONING SPECT
  • FIGURE 10: THERAPEUTIC RADIOPHARMACEUTICALS DRIVE MOST RADIOPHARMA GROWTH
  • FIGURE 11: GROWTH SHIFTS TOWARD CHINA, INDIA, AND REST OF APAC
  • FIGURE 12: THERAPEUTIC RADIOPHARMA IS THE ONLY LARGE, HIGH-GROWTH REVENUE LAYER
  • FIGURE 13: THE HIGHEST-IMPACT TECHNOLOGIES ARE AT DIFFERENT DIFFUSION STAGES
  • FIGURE 14: DOSIMETRY AND ONCOLOGY QUANTIFICATION ARE THE STRONGEST EMERGING SOFTWARE POOLS
  • FIGURE 15: COMPETITIVE ADVANTAGE IS DISTRIBUTED ACROSS FOUR CONTROL LAYERS
  • FIGURE 16: NO COMPANY CONTROLS EVERY NUCLEAR MEDICINE LAYER
  • FIGURE 17: GROWTH AND MATURITY CREATE DIFFERENT COMPETITIVE POSITIONS
  • FIGURE 18: THERAPEUTIC COMPETITION IS DIVERSIFYING ACROSS ISOTOPES, TARGETS, AND STAGES
  • FIGURE 19: COMMERCIAL SCALE REQUIRES ECOSYSTEM COLLABORATION
  • FIGURE 20: REGIONAL SHARE SHIFTS TOWARD CHINA, INDIA, AND REST OF APAC
  • FIGURE 21: REGIONAL ECONOMICS DIFFER BY REVENUE LAYER
  • FIGURE 22: REGIONAL SCENARIO DISPERSION IS WIDEST IN NORTH AMERICA, CHINA, AND EMERGING ASIA
  • FIGURE 23: CLINICAL DEMAND AND OPERATING READINESS ARE UNEVEN ACROSS PRIORITY COUNTRIES
  • FIGURE 24: FOUR REGIONAL ARCHETYPES REQUIRE DIFFERENT GO-TO-MARKET MODELS
  • FIGURE 25: CLINICAL DEMAND BECOMES REVENUE ONLY AFTER SIX CONVERSIONS
  • FIGURE 26: ISOTOPE PHYSICS DETERMINES SUPPLY-CHAIN DESIGN
  • FIGURE 27: ANNOUNCED CAPACITY IS NOT ADMINISTERED CAPACITY
  • FIGURE 28: THERAPY-SITE MATURITY IS A LADDER
  • FIGURE 29: AVAILABLE CAPACITY EQUALS THE OUTPUT OF THE WEAKEST CONTROL LAYER
  • FIGURE 30: GLOBAL MARKET SCENARIO RANGE, 2036E
  • FIGURE 31: RADIOPHARMACEUTICALS ACCOUNT FOR MOST SCENARIO DISPERSION
  • FIGURE 32: SCENARIO EXPOSURE VARIES SHARPLY BY REGION
  • FIGURE 33: THE LARGEST UPSIDE OPPORTUNITIES ALSO CARRY THE LARGEST EXECUTION RISKS